Background
==========

Osteoarthritis (OA) of the knee has long being considered primarily a cartilage disease associated with cartilage loss and degradation. However, OA is usually accompanied by changes in the subchondral and periarticular bone such as sclerosis, bone cyst and osteophyte formation \[[@B1],[@B2]\]. The relationship between the subchondral bone changes and the initiation and progression of OA is still debated \[[@B3]-[@B5]\]. Emerging evidence shows that bone turnover increases in patients with osteoarthritis with subchondral bone loss in the early stage of OA and bone formation with osteophytes in the late stage \[[@B6]-[@B9]\]. Some authors proposed the potential role of subchondral bone changes in the initiation and progression of OA \[[@B10],[@B11]\]. It was suggested that increased subchondral bone stiffness reduces the ability of knee joint to dissipate the load and distribute the forces within the joint, and increases the force load on the overlying articular cartilage, which in turn accelerates the cartilage damage over time \[[@B6],[@B9]\]. Therefore, the functional integrity of the articular cartilage depends on the mechanical properties of the subchondral bone. For early osteoarthritis of the knee, the initial focus of treatment on articular cartilage or in subchondral bone remains controversial.

Extracorporeal shockwave therapy (ESWT) has shown effectiveness in many orthopedic disorders including soft tissue tendinopathy and non-union of long bone fractures \[[@B12],[@B13]\]. In addition, many studies reported positive effects of ESWT in various arthritic joints in animals \[[@B14]-[@B18]\]. Other studies demonstrated that ESWT is chondroprotective in the initiation of OA changes of the knee \[[@B19]\], and induces regression or retardation of established OA changes of the knee in rats \[[@B20]\]. The ESWT dosages in the studies were based on the results of a pilot study that demonstrated 800 impulses of shockwave at 14 Kv applied to the subchondral bone of the medial tibia condyle showed better effects than 200, 400 and 1200 impulses in small animals. However, the optimal dosage and the ideal number of ESWT in osteoarthritis of the knee are unknown. Furthermore, many studies reported a dose-related effect of ESWT in bone \[[@B21]\], tendon \[[@B22]\], epigastric skin flap \[[@B23]\], tenocyte \[[@B24]\], and cells \[[@B25]\]. We hypothesized that the effect of ESWT in osteoarthritis of the knee may be related to the number of ESWT treatment. The purpose of this study was to investigate the effect of different numbers of ESWT treatment in osteoarthritis of the knee in rats.

Methods
=======

The Institutional Review Board on animal experiment of Chang Gung Memorial Hospital, Taiwan approved this study. All studies were performed in accordance with the guidelines in the study and the care of animals in experiment.

Study design
------------

This study was performed in 45 male Sprague-Dawley rats of 10-week old with body weight ranging from 275 mg to 315 mg. The anterior cruciate ligament transected (ACLT) and medial meniscectomized (MM) osteoarthritis knee model in rat was used \[[@B8]\]. The animals were divided into five groups with 9 rats in each group. Group I was the control and underwent sham arthrotomy of the knee without ACLT or MM and received no ESWT. Group II underwent ACLT and MM but no ESWT. Group III underwent ACLT + MM and received ESWT once a week for one treatment. Group IV underwent ACLT and MM and received ESWT twice a week for two treatments. Group V underwent ACLT and MM and received ESWT three times a week for three treatments. Radiographs of the knee in anteroposterior and lateral projections were performed at 0 and 12 weeks. Radiographs of the knee were obtained to assess bony appearance, focal osteoporosis, narrowing of joint space and spur formation. The animals were sacrificed at 12 weeks and the knee specimens were subjected to histomorphological examination and immunohistochemical analysis.

Anterior cruciate ligament transection and medial meniscectomy
--------------------------------------------------------------

The animals were sedated with intra-peritoneal phenobarbital injection (50 mg/Kg body weight). The left knee was prepared and draped in surgically sterile fashion. A straight anterior skin incision was made and the knee joint was opened through medial parapatellar arthrotomy. The anterior cruciate ligament was transected with a scalpel. Medial meniscectomy was performed by excising the entire medial meniscus. The knee was irrigated and the wound was closed in routine fashion. The animals were returned to the housing cages and were under the care of the veterinarian.

Shockwave application
---------------------

ESWT was administered in groups III, IV and V in one week after knee surgery when the wound healed. The animals were sedated with intra-peritoneal phenobarbital injection (50 mg/Kg body weight). The source of shockwave is from an OssaTron orthotriptor (Sanuwave, Alpharetta, GA). The focus of shockwave treatment was the subchondral bone of the medial tibia condyle that was approximately 0.5 cm below the medial tibia plateau in anteroposterior view and 0.5 cm from the medial skin in lateral view (Figure [1](#F1){ref-type="fig"}). The depth of treatment was confirmed with the laser indicator of the shockwave device. Ultrasound gel was applied to the skin in contact with the shockwave tube. Each treatment consisted of the application of 800 impulses of shockwave at 14 Kv (equivalent to 0.22 mJ/mm^2^). ESWT was performed once in group III, twice in group IV and three times in group V. After ESWT, the animals were returned to the housing cages and are under the care of the veterinarian.

![A knee sketch shows the location of shockwave application in A-P (1-A) and lateral view (1-B).](1471-2474-14-44-1){#F1}

Histomorphological examination
------------------------------

The animals were sacrificed at 12 weeks. The knee specimens including the articular cartilage and the subchondral bone of proximal tibia and distal femur were harvested. The specimens were decalcified and fixed in paraffin, and cut into 5-um thick sections using microderme and stained with heamtoxylin-eosin, Safranin-O, thionine and Alcian blue stains. The microscopic features of the articular cartilage included fissuring of the cartilage, chondrocyte proliferation, chondrocyte activity and chondrocyte apoptosis. The cartilage degradation was assessed by Mankin score that included cartilage structure, cartilage cells and tidemark integrity \[[@B26]\]. The matrix content was measured with Safranin O staining. The subchondral bone remodeling was evaluated with tissue distributions including cortical bone, cancellous bone and fibrous tissue.

Immunohistochemical analysis
----------------------------

The specimens were fixed in 4% PBS-buffered paraformaldehyde for 48 hours and decalcified in PBS-buffered 10% EDTA. Decalcified tissues were embedded in paraffin. The specimens were cut longitudinally into 5-um thick sections and transferred to poly-lysine-coated slides. Sections of the specimens were immunostained with specific reagents for vWF (von Willebrand Factor), VEGF (vessel endothelial growth factor), BMP-2 (bone morphogenic protein 2) and osteocalcin in subchondral bone, and MMP13 (matrix metalloproteinase 13) and collagen II in articular cartilage (Santa Cruz Biotechnology Inc, CA, USA). The immuno-reactivity in specimens was demonstrated using a horseradish peroxidase (HRP)-3′-, 3′-diaminobenzidine (DAB) cell and tissue staining kit (R & D Systems, Inc. Minneapolis, MN, USA). The immuno-activities were quantified from five areas in three sections of the same specimen using a Zeiss Axioskop 2 plus microscope (Carl Zeiss, Gottingen, Germany). All the images of each specimen were captured using a Cool CCD camera (SNAP-Pro c.f. Digital kit; Media Cybernetics, Sliver Spring, MD, USA). Images were analyzed using an Image-Pro® Plus image-analysis software (Media Cybernetics, Sliver Spring, MD, USA). The percentage of positive immuno-labeled cells over the total cells in each area was counted. A pathologist blinded to the nature of the study performed the measurements on all sections. The cartilage degradation was assessed with the measurements of MMP-13 and collagen II in the articular cartilage, and the subchondral bone remodeling by the measurements of vWF, VEGF, BMP-2 and osteocalcin.

Statistical analysis
--------------------

The results of this study were expressed in median with ranges. Group I data were used as the baseline for statistical comparison with other groups. The P-values were obtained using ANOVA and post hoc test with Bonferoni correction among five groups, and Mann-Whitney "*U*" test between two groups. A statistical significance was set at p \< 0.05.

Results
=======

Radiographs of the knee showed no discernable difference among the 5 groups at 0 week. However, at 12 weeks, groups II and V showed more radiographic arthritis than groups I, III and IV (Figure [2](#F2){ref-type="fig"}).

![Radiographs of the knee at 12 weeks show more advanced osteoarthritis of the knee in groups II and V, and less arthritic changes in groups I, III and IV.](1471-2474-14-44-2){#F2}

The results of Mankin score and Safranin O matrix staining are summarized in Table [1](#T1){ref-type="table"} and Figure [3](#F3){ref-type="fig"}. The microscopic features are shown in Figure [4](#F4){ref-type="fig"}. The Safranin O matrix staining in group III and IV is significantly better than in groups II and V, and the Mankin scores in groups III and VI are less than groups II and V. The figures reflect a decreased Safranin O staining and an increased Mankin score associated with progression of osteoarthritis of the knee. The knees that were treated with one and two ESWT treatments showed significantly better Mankin score and Safranin O staining than knees treated with three ESWT treatments.

![The results of Mankin score and Safranin O stain.](1471-2474-14-44-3){#F3}

![Microscopic features of the articular cartilage and subchondral bone in histomorphological examination.](1471-2474-14-44-4){#F4}

###### 

The results of Mankin score and Safranin O stain

  ------------------ -------------- --------------- -------------- --------------
   **Mankin score**                                                       
     **Group I**      **Group II**   **Group III**   **Group IV**   **Group V**
       1 (1-1)         10 (9-12)        1 (0-2)        3 (2-4)       10 (8-11)
                      P1 = 0.0088       P2 = 1       P3 = 0.0742    P4 = 0.0102
                                      P5 = 0.0017    P6 = 0.0038    P7 = 0.6213
                                                     P8 = 0.0705    P9 = 0.0022
                                                                    P10 = 0.0052
    **Safranin O**                                                        
     **Group I**      **Group II**   **Group III**   **Group IV**   **Group V**
       1 (1-1)        18.7 (16-20)     0.7 (0-1)      1.3 (1-2)      15 (12-17)
                      P1 = 0.0056     P2 = 0.4226    P3 = 0.4226    P4 = 0.0117
                                      P5 = 0.0036    P6 = 0.0039    P7 = 0.1461
                                                     P8 = 0.2302    P9 = 0.0087
                                                                    P10 = 0.0096
  ------------------ -------------- --------------- -------------- --------------

Group I: the control; Group II: ACLT + MM; Group III: ACLT + MM + ESWT 1×/week; Group IV: ACLT + MM + ESWT 2×/week; Group V: ACLT + MM + ESWT 3×/week.

ACLT: anterior cruciate ligament transection; MM: medial meniscectomy; ESWT: extracorporeal corporeal shockwave therapy.

P1: Group I vs Group II P2: Group I vs Group III P3: Group I vs Group IV.

P4: Group I vs Group V P5: Group II vs Group III P6: Group II vs Group IV.

P7: Group II vs Group V P8: Group III vs Group IV P9: Group III vs Group V.

P10: Group IV vs Group V.

The P values were obtained using ANOVA and post hoc test with Bonferoni correction among five groups, and the Mann-Whitney *U* test between two groups.

The results of MMP13 and collagen II of the articular cartilage are summarized in Table [2](#T2){ref-type="table"} and Figure [5](#F5){ref-type="fig"}. The microscopic features are shown in Figure [6](#F6){ref-type="fig"}. Group II showed significant increase of MMP13 and decreases of collagen II as compared to group I indicating the progression of the knee arthritis. The changes of MMP-13 and collagen II in groups III and IV were comparable to group I, however, the changes in group V are closely similar to group II.

![The results of MMP13 and collagen II in articular cartilage.](1471-2474-14-44-5){#F5}

![Microscopic features of MMP13 and collagen II in articular cartilage in immunohistochemical stains.](1471-2474-14-44-6){#F6}

###### 

The results of MMP13 and collagen II in articular cartilage

  --------------------- ------------------ ---------------- ------------------ ------------------
      **MMP13 (%)**                                                                     
       **Group I**         **Group II**     **Group III**      **Group IV**       **Group V**
      11.2 (9.4-12)      83.1 (79.5-89.3)   9.4 (7.8-11.3)   22.9 (11.8-27.3)   89.1 (88.5-92.4)
                           P1 = 0.0008       P2 = 0.3467       P3 = 0.1643        P4 \< 0.0001
                                             P5 = 0.0005       P6 = 0.0008        P7 = 0.1578
                                                               P8 = 0.1307        P9 \< 0.0001
                                                                                  P10 = 0.0027
   **Collagen II (%)**                                                                  
       **Group I**         **Group II**     **Group III**      **Group IV**       **Group V**
    83.7 (80.4-87.5)     10.4 (7.6-11.7)    76 (73.7-82.1)    77.5 (76-83.7)    12.4 (11.5-14.5)
                           P1 \< 0.0001      P2 = 0.1142       P3 = 0.2007        P4 = 0.0001
                                             P5 = 0.0002       P6 = 0.0001        P7 = 0.1319
                                                               P8 = 0.6280        P9 = 0.0005
                                                                                  P10 = 0.0003
  --------------------- ------------------ ---------------- ------------------ ------------------

P1: Group I vs Group II P2: Group I vs Group III P3: Group I vs Group IV.

P4: Group I vs Group V P5: Group II vs Group III P6: Group II vs Group IV.

P7: Group II vs Group V P8: Group III vs Group IV P9: Group III vs Group V.

P10: Group IV vs Group V.

The P values were obtained using ANOVA and post hoc test with Bonferoni correction among five groups, and the Mann-Whitney *U* test between two groups.

The results of vWF, VEGF, BMP-2 and osteocalcin in subchondral bone are summarized in Table [3](#T3){ref-type="table"} and Figure [7](#F7){ref-type="fig"}. The microscopic features are shown in Figure [8](#F8){ref-type="fig"}. Group II showed significant decreases of vWF, VEGF, BMP-2 and osteocalcin as compared to group I. Group III and IV showed significant increases of vWF, VEGF, BMP-2 and osteocalcin with the data comparable to group I. However, group V showed significant decreases of vWF, VEGF, BMP-2 and osteocalcin comparable to group II. It appears that one or two ESWT treatments showed beneficial effects, however, three ESWT treatments caused deteriorating changes.

![The results of vWF, VEGF, BMP-2 and osteocalcin in subchondral bone.](1471-2474-14-44-7){#F7}

![**Microscopic features of vWF, VEGF.** BMP-2 and osteocalcin in subchondral bone in immunohistochemical stains.](1471-2474-14-44-8){#F8}

###### 

The results of vWF, VEGF, BMP-2 and osteocalcin in subchondral bone

  ------------------ ------------------ ------------------ ------------------ ------------------
     **vWF (%)**                                                                       
     **Group I**        **Group II**      **Group III**       **Group IV**       **Group V**
   81.9 (78.9-86.8)   16.2 (15.4-19.5)   84.8 (79.7-89.1)   73.8 (62.9-78.3)   17.6 (13.1-20.3)
                        P1 = 0.0001        P2 = 0.8696        P3 = 0.1253        P4 \< 0.0001
                                           P5 = 0.0012        P6 = 0.0044        P7 = 0.9899
                                                              P8 = 0.1156        P9 = 0.0004
                                                                                 P10 = 0.0022
     **VEGF (%)**                                                                      
     **Group I**        **Group II**      **Group III**       **Group IV**       **Group V**
    82.8 (79-84.6)    15.4 (11.2-19.5)   72.5 (68.6-80.4)   78.3 (73.8-83.5)   13.1 (11.3-17.6)
                        P1 = 0.0001        P2 = 0.1239        P3 = 0.3432        P4 \< 0.0001
                                           P5 = 0.0003        P6 = 0.0001        P7 = 0.6777
                                                              P8 = 0.3540        P9 = 0.0005
                                                                                 P10 = 0.0001
     **BMP2 (%)**                                                                      
     **Group I**        **Group II**      **Group III**       **Group IV**       **Group V**
    84.4 (77.1-91)    11.2 (9.4-15.4)    74.6 (73.1-89.1)   72.9 (68.3-73.8)   13.1 (12.4-14.6)
                        P1 = 0.0008        P2 = 0.4670        P3 = 0.0729        P4 = 0.0026
                                           P5 = 0.0027        P6 \< 0.0001       P7 = 0.5312
                                                              P8 = 0.2893        P9 = 0.0054
                                                                                 P10 = 0.0002
     **OCN (%)**                                                                       
     **Group I**        **Group II**      **Group III**       **Group IV**       **Group V**
   79.6 (69.6-82.2)   10.5 (9.4-11.2)    76.7 (76.1-87.8)   73.8 (62.9-77.3)    9.1 (8.5-12.4)
                        P1 = 0.0029        P2 = 0.6008        P3 = 0.3741        P4 = 0.0016
                                           P5 = 0.0025        P6 = 0.0045        P7 = 0.8010
                                                              P8 = 0.2002        P9 = 0.0014
                                                                                 P10 = 0.0029
  ------------------ ------------------ ------------------ ------------------ ------------------

P1: Group I vs Group II P2: Group I vs Group III P3: Group I vs Group IV.

P4: Group I vs Group V P5: Group II vs Group III P6: Group II vs Group IV.

P7: Group II vs Group V P8: Group III vs Group IV P9: Group III vs Group V.

P10: Group IV vs Group V.

The P values were obtained using ANOVA and post hoc test with Bonferoni correction among five groups, and the Mann-Whitney *U* test between two groups.

Discussion
==========

The results of the current study showed that ESWT protects the articular cartilage degradation and improves subchondral bone remodeling in the initiation of osteoarthritis of the knee in rats. The results are in agreement with prior studies that shockwave has chondroprotective effect in OA knee in rats \[[@B19],[@B20]\], The subchondral bone remodeling relies on the balance between bone formation by osteoblast and bone resorption by osteoclast, and is influenced by the subchondral bone mass and bone strength. The effects on articular cartilage were supported by the changes of Mankin score, Safranin O stain, MMP-13 and collagen II. MMP-13 is involved in cartilage turnover and cartilage pathophysiology associated with osteoarthritis. Collagen II is the base of articular cartilage and hyaline cartilage that form fibrillar network of collagen that allows cartilage to entrap the proteoglycan aggregate and provide tensile strength to the tissue. The effects of ESWT in subchondral bone remodeling were supported by the increased vascularization manifested by the changes of vWF, eNOS and VEGF, and osteogenesis manifested by the changes in BMP-2, alkaline phosphatase and osteocalcin. vWF is a large glycoprotein in plasma and endothelium and a positive vWF is indicative of new vessel formation. eNOS is an immune transmitter and vasodilator in tissue healing . VEGF is a protein that stimulates vasculogenesis and angiogenesis and an indication of increased vascular permeability and microvascular activities including the angiogenic growth of new vessels. BMP-2 is osteoinductive and induces osteoblast differentiation. Alkaline phosphatase is a hydrolase enzyme responsible for dephosphorylation. Osteocalcin is pre-osteoblastic and bone-building in nature.

The current study also demonstrated that ESWT has a number of treatment related effect in osteoarthritis of the knee. Many studies reported dose-dependent effects of ESWT in different tissues \[[@B21]-[@B25]\]. ESWT showed a dose-related enhancement in bone mass and bone strength after fracture of the femur in rabbits \[[@B21]\]. Other study reported a dose-related effect of shockwaves on rabbit tendon Achilles \[[@B22]\]. In a murine skin flap model, ESWT between 500 and 2500 impulses showed a dose-dependent effect in epigastric flap survival \[[@B23]\]. ESWT also showed dose-dependent changes in cell viability, MMP 1, 2 and 3 and IL-6 on cultured tenocytes \[[@B24]\]. Another study stated that one of the most important aspects to be considered is not the total number of impulses used but the energy level of the shockwaves, thus confirming that ESWT has a dose-dependent effect on osteoblast cells \[[@B25]\]. An optimal ESWT dosage may result in beneficial effects, whereas, overdose of ESWT can cause deteriorating effect and damage to the subchondral bone and articular cartilage of the knee. The current study demonstrated that one or two ESWT treatments showed beneficial effect, however, three ESWT treatments caused deteriorating results. Additional studies including clinical trial are needed to validate the ideal numbers of ESWT for osteoarthritis of the knee in humans.

The exact mechanism of ESWT remains unknown. Recent studies showed that ESWT induces the ingrowth of neovascularization and up-regulation of angiogenic and osteogenic growth factors that leads to improvement in blood perfusion and tissue regeneration \[[@B27]\]. The innovative findings in this study may unveil a new concept in the management of osteoarthritis of the knee by shifting the initial treatment focus from the articular cartilage to the subchondral bone. Furthermore, ESWT has the potential used in the treatment of osteoarthritis of the knee.

There are limitations in this study. The data obtained from this study were based on experiments in small animals. The results may differ in larger animals or human subjects. The dose conversion (energy level and the total energy) from small animals to larger animals or human subjects must be validated with additional studies including clinical trial. This study demonstrated that the effect of ESWT is related to the number of treatment, but not necessarily the dosage in knee OA, and the optimal ESWT dosage and the ideal numbers of ESWT treatment remains unknown. Furthermore, different manufacture companies used different indices of shockwave parameters, and the dose conversion formula among the different devices are not readily available at the present time.

Conclusion
==========

ESWT shows a number of treatment related chondroprotective effects and improves subchondral bone remodeling in the initiation of osteoarthritis of the knee in rats. Additional studies are needed to validate the optimal ESWT dosage and the number of treatment for osteoarthritis of the knee.
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